The DOI matches its Crossref record.
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors
Open accessAbstract
At least 56 matrix metalloproteinase (MMP) inhibitors have been pursued as clinical candidates since the late 1970's when the first drug discovery program targeting this enzyme family began. Some of these clinical candidates were pursued for multiple indications. However, the two primary indications that have been targeted are cancer (24 drugs) and anti-arthritis (27 drugs). Cardiovascular disease was listed as an indication for 10 drugs. Forty-six MMP inhibitors have been discontinued, 7 remain in clinical development, and only 1 (Periostat for periodontal disease) has been approved. Recently, negative phase II results were reported for the MMP inhibitor PG-116800, which was being evaluated as a treatment for post-ischemic myocardial remodeling to prevent heart failure. One major factor leading to the failure of PG-116800 and many of the other MMP inhibitors is the inadequate assessment of the therapeutic index, the ratio of dose required for efficacy vs. that for toxicology. This review describes the dose-limiting side effect that has hampered MMP inhibitor development (the musculoskeletal syndrome), cardiovascular clinical MMP inhibitor studies, a model of the therapeutic index using marimastat, and progress towards more selective MMP inhibitors not limited by the musculoskeletal syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Spinale, F. G. (2007) · Physiological Reviews · doi:10.1152/physrev.00012.2007 · Cited by 1,120
MMP13 is a critical target gene during the progression of osteoarthritis
Wang, M., Sampson, E. R., Jin, H., Li, J., Ke, Q. H., Im, H.-J., & Chen, D. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4133 · Cited by 508
Breaching the basement membrane: who, when and how?
Rowe, R. G., & Weiss, S. J. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.007 · Cited by 443
The Role of Chondrocyte Hypertrophy and Senescence in Osteoarthritis Initiation and Progression
Rim, Y. A., Nam, Y., & Ju, J. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072358 · Cited by 382
Macrophage roles following myocardial infarction
Lambert, J. M., Lopez, E. F., & Lindsey, M. L. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.04.059 · Cited by 339
Metadata
- Authors
- PETERSON, J.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-15
- Volume
- 69
- Issue
- 3
- Pages
- 677-687
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2157935582
- Cited by
- 196
- References
- 0
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. https://app.cochat.ai/papers/10.1016/j.cardiores.2005.11.032
- The paper
- PETERSON, J. (2006). The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovascular Research. https://doi.org/10.1016/j.cardiores.2005.11.032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.